SEE THE PAST SPEAKERS & CASE STUDIES
FROM LAST ANNUAL

Peter
ETTMAYER
Director New Therapeutic Discovery
Mikhail
KALINICHEV
Director, in vivo Neurology
Mathew
WOODWARK
Director Research Informatics
Ulrich
BETZ
Vice President Innovation, Head of Department Innovation Incubator
Philippe
SANSEAU
Head Computational Biology and Stats
Antoine
BRIL
Scientific Director Research and Partnerships

 

PAST CASE STUDIES INCLUDE

Antoine BRILScientific Director Research And Partnerships
Servier

Collaborative Strategies To Increase Efficiency In Drug Discovery

The presentation will describe the collaborative approaches needed to reinforce efficiency in the drug discovery enterprise. The Innovative Medicine Initiative has produced dramatic changes in the way drug discovery is conducted not only with delivery of models and methods, but mainly with a change in mindset among actors. Similarly, research activities are performed in projects that need interdisciplinary partnerships and collaborations at various levels: data to knowledge, science to medicine, biology to patient.

  • Technologies such as imaging, augmented intelligence, robotic, and many other technologies, fundamentally change the way drug discovery is done.
  • Collaborative approaches are needed to embrace the complexity needed to progress drug discovery projects.
  • Partnerships are between academic scientists, small and medium enterprises, industries, such as in the Innovative Medicine Initiative (IMI), but also within research centres.
Mathew WoodwarkDirector Research Informatics
MedImmune

Integrative Informatics: A Hybrid Approach To Integrating Data For Drug Discovery

MedImmune, the Biologics arm of AstraZeneca is working towards integrative informatics. The aim is to apply query driven semantic approaches to identifying, selecting and integrating data sets relevant to answering complex scientific questions. The approach combines linked data with traditional bioinformatics workflow and pipeline management to enable flexible data integration and utilisation without building an enterprise data warehouse.

  • Hybrid approach of semantic modelling and analytical pipelines
  • FAIR data is key
  • Leaving data in place and applying federation techniques
  • Integration goes hand in hand with data management
  • Ability to use clinical data in an exploratory context drives translational success
Ulrich BetzVice President Innovation, Head Of Department Innovation Incubator
Merck

Innovation Now – The Future Doesn’t Wait

Merck, the world’s oldest pharmaceutical and chemical company, is celebrating its 350th anniversary in 2018. Over the course of these 350 years, Merck has evolved to a global leading science and technology company in healthcare, life science, and performance materials with approximately 50,000 employees around the world. The Merck family has remained the majority owner of the company to this very day. Merck develops technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. The talk will present special innovation activities Merck is running on the occasion of its 350th anniversary.

  • Innovation – a buzzword for life or death
  • Game changers – the future doesn’t wait
  • 350 years of curiosity & innovation and an offer to the world for collaboration
  • Curious2018-Future InSight Conference – the brightest minds coming together to explore the future of science & technology
  • Merck Innovation Cup – Cross-generational innovation to cover unmet medical need
Mikhail KALINICHEVDirector, In Vivo Neurology
Ipsen

Increasing Translational Value Of Animal Models In Drug Discovery

The success rates of drugs in clinical development remain low, as too often their activity in animal models fails to translate into efficacy in clinical studies. The lack of translational value in animal models has been named as one explanation of clinical failures. Thus, critical assessment of the current use of animal models in drug discovery is essential.

  • Selection of the animal model, its face, construct and predictive validity; back translation of clinical activity
  • Rigorous design, execution, and analysis of pre-clinical studies
  • Impact of pre-clinical studies on therapeutic strategy of the drug

WE ARE LOOKING FORWARD TO WELCOMING YOU ON BOARD IN 2019!

2018 CONFERENCE TOPICS

  • Open innovation as a new business model in Pharma R&D
  • External collaboration and partnerships in R&D
  • The Innovative Medicine Initiative and the changes in drug discovery
  • New technologies in drug discovery – imaging, robotics, and augmented intelligence
  • Impact of pre-clinical studies on therapeutic strategy of the drug
  • Strategic Data integration
  • Artificial Intelligence and Machine Learning in R&D
  • China as one of the strategically important markets for new drug research
  • Special innovation activities Merck is running on the occasion of its 350th anniversary

WHAT DELEGATES SAID

DESIGNED FOR

Members of board, C-level, Senior Vice Presidents, Vice Presidents, Directors, and Heads of departments from pharmaceutical industry involved in:

  • R&D
  • Drug Discovery
  • Drug Development
  • Clinical Development
  • Open Innovation
  • Early research and development
  • Innovation
  • External Innovation
  • External collaboration
  • Alliance Management and Partnerships
  • Artificial Intelligence
  • Machine Learning
  • Translational Medicine
  • R&D Information Technology
  • R&D Analytics
  • New Technology
  • Bioinformatics

PRE-CONFERENCE WORKSHOPS

Workshop A

Innovations emerging in Pharma R&D

  • The Intersection of Technology and Biology – using the innovative digital technologies as a tool to interrelate the biology and technology more than ever before, and thus improve the healthcare
  • Nanotechnology and its advantages in Pharma R&D – possibility to track taken medications and potential use of microscopic robots, programmed to perform a task inside of human body
  • Use of 3D printing to reduce the costs in R&D and bring effective drugs faster to the market. What are the challenges, benefits, and safety concerns, and how to overcome regulatory hurdles?
  • Incorporating the Open Science into R&D by methods as: Goal-directed collaboration, Open Data, Crowdsourcing, and Open Source

Workshop B

The Future of adoption the Virtual R&D

  • How many years will it take to R&D to create the virtual body that will be able to predict the effects of modulating a biological target on the whole system?
  • Current vs. Future development process – starting with designing the treatment except for molecule and possibility to take the pain out of the process completely
  • What are the changing needs of society and how can pharmaceutical companies meet them most effectively?
  • Bringing new treatments to the market by implementing collaboration and developing more innovative products, which can bring additional benefits to patients, healthcare providers, and payers

SPONSORS 2018

STAY UPDATED FOR NEXT ANNUAL

Provide us with your contact details and our team will get back to you with all the updates regarding the upcoming edition of this event.